Aim Bulletin

Hutchmed China upbeat on results from lung cancer trial

By Josh White

Date: Monday 02 Jun 2025

(Sharecast News) - Hutchmed China reported positive interim results from its phase three 'SACHI' trial on Monday, showing that the combination of savolitinib and osimertinib significantly improved progression-free survival (PFS) in patients with advanced EGFR mutation-positive non-small cell lung cancer (NSCLC) and MET amplification, following progression on first-line EGFR inhibitor therapy.

Sign up for free or to read the full story

Email this article to a friend

or share it with one of these popular networks:


Article Archive

Top of Page